ACADIA Pharmaceuticals Inc. (ACAD) 주식 분석

회사 개요

ACADIA Pharmaceuticals Inc. is a biopharmaceutical enterprise dedicated to the development and commercialization of therapeutic agents targeting neurological conditions and rare diseases within the North American market. The company operates within the broader Healthcare sector, specifically specializing in the Biotechnology industry, which implies a focus on high-risk, high-reward research and development cycles driven by intellectual property and clinical trial success. As of the latest reported data, ACADIA holds a market capitalization of $3.85B and generates annual revenue of $1.07B, supported by a workforce of 796 employees. These financial figures position the firm as a significant mid-to-large cap player within the specialized biopharmaceutical landscape, indicating a substantial operational footprint capable of funding complex drug development programs while maintaining a meaningful revenue base from its core product portfolio, notably including NUPLAZID (pimavanserin).

재무 건전성

ACADIA reported a trailing twelve-month revenue of $1.07B, alongside a net income of $391.00M and an EBITDA of $116.57M. The substantial gap between the $1.07B in revenue and the $391.00M in net income reveals a highly efficient cost structure, suggesting that the company retains a significant portion of its top-line growth after accounting for operating expenses, taxes, and interest. However, the free cash flow stands at -$54,821,124, indicating that despite profitable operations, the company is currently burning cash, likely due to heavy capital expenditures or working capital requirements associated with its growth phase. This negative cash flow status suggests limited immediate financial flexibility for aggressive expansion without external financing, although the company holds $819.69M in cash reserves. The company maintains a gross margin of 61.0%, an operating margin of 6.1%, and a profit margin of 36.5%. The high gross margin reflects the typical economics of selling patented pharmaceuticals, while the lower operating and profit margins indicate significant investment in research, sales, and administrative functions. Regarding leverage, the company holds $819.69M in cash against $52.19M in debt, resulting in a debt-to-equity ratio of 4.25. Despite the elevated debt-to-equity figure, the overwhelming cash position suggests a conservative balance sheet that is effectively insulated from liquidity shocks. The current ratio of 3.83 further demonstrates robust short-term liquidity, confirming the ability to cover current liabilities well more than three times over. Finally, the return on equity is 39.9% while return on assets is 4.8%, revealing that management is generating highly efficient returns on shareholder capital, even though the asset base generates a lower percentage return due to the specific capital intensity of the biotechnology sector.

밸류에이션 평가

The trailing twelve-month P/E ratio is 9.81, while the forward P/E is projected at 24.53. This significant disparity between the current and forward valuation multiples implies that the market expects a substantial increase in earnings in the coming years to justify the higher future multiple, reflecting an anticipated growth trajectory rather than current profitability levels. The price-to-book ratio stands at 3.13, which indicates that the market values the company at a significant premium over its tangible book value, a common characteristic for biotechnology firms with substantial intangible assets like patents and clinical data. Alternative valuation metrics such as the price-to-sales ratio of 3.59 and an EV/EBITDA of 26.43 suggest that the company is priced based on future growth potential and revenue scalability rather than current earnings power. The stock has traded between a 52-week high of $28.35 and a 52-week low of $13.40, providing a clear range for historical volatility analysis. The beta of 0.83 indicates that the stock's price volatility is lower than the broader market, suggesting it may act as a defensive holding relative to the overall equity market during periods of instability.

Growth & Income

ACADIA is experiencing revenue growth of 9.4% year-over-year, while earnings growth is significantly higher at 86.2% year-over-year. The fact that earnings are growing at a rate far exceeding revenue growth implies that the company is achieving greater operational efficiency or benefiting from pricing power and margin expansion as it scales its product portfolio. Since ACADIA does not currently pay dividends, the dividend yield is N/A and the payout ratio is 0.0%. This absence of dividend distribution means the company retains all of its earnings to reinvest into research and development, manufacturing capacity, and commercialization efforts rather than distributing income to shareholders. The overall growth and income profile for ACADIA is characterized by rapid earnings acceleration and a zero-dividend strategy that prioritizes long-term value creation through reinvestment.